Compare Lumen Technologies Inc (LUMN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs 10X Genomics Inc — how do they compare? Lumen Technologies Inc trades at $5.3 (market cap $5.73B), while 10X Genomics Inc trades at $81 (market cap $10.07B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and 10X Genomics Inc for 91 Days on average.
| LUMN | TXG | |
|---|---|---|
Market Cap | $5.73B | $10.07B |
Volume | 17,079,799 | 5,657,286 |
Sector | Media | Health |
52-Week High | $11.83 | $97.74 |
52-Week Low | $5.53 | $11.48 |
Typical Hold Time | 40 Days | 91 Days |
Enterprise Value | $17.35B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $5.20, down 12.01% in 24 hours, reflecting bearish technical signals and negative profitability. Revenue declined to $12.40B in 2025 with a net loss of $1.74B, though recent product launches like Intelligent Internet target AI-driven growth. The stock faces high debt levels at $17.49B long-term, while analyst consensus is predominantly Hold (60.71%) with a Reduce rating average.
The outlook remains challenged by legacy revenue declines and substantial debt, but strategic pivots to AI networking offer speculative upside. Key risks include persistent losses and competitive pressures, requiring careful monitoring of cash flow and execution on new initiatives for any sustained recovery.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
